Strain-specific efficacy of Limosilactobacillus reuteri DSM 17648 in Helicobacter pylori: eradication therapy: A systematic review and meta-analysis

Introduction. The declining efficacy of the standard regimens for the eradication of Helicobacter pylori (H. pylori) and the development of adverse events when prescribed antibacterial therapy substantiates the search for strain-specific adjuvant approaches that can improve the tolerability and efficacy of treatments.

Aim. To systematize data on the effect of Limosilactobacillus reuteri (L. reuteri) DSM 17648 on the efficacy and safety of H. pylori eradication therapy.

Materials and methods. In accordance with PRISMA 2020 statement, a comprehensive literature search was conducted using MEDLINE/PubMed, Embase, Cochrane Library, Scopus, and the Russian Science Citation Index (RSCI) to identify relevant studies published between January 1, 2007 and March 10, 2026. The systematic review and meta-analysis protocol was entered into the PROSPERO database (CRD420261355068). The meta-analysis included the studies of L. reuteri DSM 17648 used as an adjuvant treatment to the standard eradication therapy, as well as studies exploring its effect on H. pylori bacterial load.

Results. Ten studies were included; the analysis of the efficacy of adjuvant therapy included seven comparative studies involving 1,217 patients. There was a significant increase in eradication efficacy as compared with the control group when L. reuteri DSM 17648 was given as part of H. pylori therapy (RR 1.088, 95% CI: 1.029–1.150; p = 0.003). The eradication rate was 93.6% versus 83.5% in the control group. The L. reuteri DSM 17648 group demonstrated a lower overall rate of incidence adverse events (RR 0.708, 95% CI: 0.591–0.850; p < 0.001), including the risk of diarrhea (RR 0.586, 95% CI: 0.387–0.886; p = 0.011). A separate analysis showed that the groups receiving L. reuteri DSM 17648 had a significant reduction in bacterial load as measured by the 13C-urea breath test (standardized mean difference: -0.416, 95% CI -0.749 to -0.083; p = 0.014).

Conclusions. This strain-specific systematic review and meta-analysis demonstrated that supplementation of L. reuteri DSM 17648 to H. pylori treatment regimens was associated with higher eradication efficacy and an improved safety profile.

1. Chen Y-C, Malfertheiner P, Yu H-T, Kuo C-L, Chang Y-Y, Meng F-T et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024;166(4):605–619. https://doi.org/10.1053/j.gastro.2023.12.022.

2. Hu Y, Du R, Lai Y, Hu Y, Zhu Y, Zhou Y et al. 40 years after the discovery of Helicobacter Pylori : Performing optimized “subtraction” for clinical eradication. IMetaOmics. 2025;2(2):e70017. https://doi.org/10.1002/imo2.70017.

3. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553–564. https://doi.org/10.1016/S2468-1253(23)00070-5.

4. Lemos FFB, Castro CT de, Calmon MS, Silva Luz M, Pinheiro SLR, Faria Souza Mendes Dos Santos C et al. Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis. World J Gastroenterol. 2023;29(14):2202–2221. https://doi.org/10.3748/wjg.v29.i14.2202.

5. Collatuzzo G, Dajti E, Secco M, Bazzoli F, Boffetta P, Zagari RM. Burden of gastric cancer attributable to Helicobacter pylori in 27 countries from seven geographic regions in 2022. Gastric Cancer. 2026;29(1):16–26. https://doi.org/10.1007/s10120-025-01677-9.

6. Andreev DN, Khurmatullina AR, Maev IV, Bordin DS, Abdulkhakov SR, Kucheryavyy YA et al. The Prevalence of Helicobacter pylori Infection in the Adult Population of Russia: A Systematic Review and Meta-Analysis. Epidemiologia. 2025;6(3):47. https://doi.org/10.3390/epidemiologia6030047.

7. Andreev DN, Khurmatullina AR, Bordin DS, Maev IV. Trends in the prevalence of Helicobacter pylori infection among adults in Moscow: a systematic review and meta-analysis. Ter Arkh. 2025;97(5):463–470. https://doi.org/10.26442/00403660.2025.05.203250.

8. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J-M, Schulz C et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762. https://doi.org/10.1136/gutjnl-2022-327745.

9. Bordin DS, Livzan MA, Osipenko MF, Mozgovoy SI, Andreyev DN, Maev IV. The key statements of the Maastricht VI consensus. Exp Clin Gastroenterol. 2022;9:5–21. https://doi.org/10.31146/1682-8658-ecg-205-9-5-21.

10. Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119(9):1730–1753. https://doi.org/10.14309/ajg.0000000000002968.

11. Ivashkin VT, Lapina TL, Maev IV, Drapkina OM, Kozlov RS, Sheptulin AA et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72–93. (In Russ.) https://doi.org/10.22416/1382-4376-2022-32-6-72-93.

12. Mladenova I. Epidemiology of Helicobacter pylori Resistance to Antibiotics (A Narrative Review). Antibiotics. 2023;12(7):1184. https://doi.org/10.3390/antibiotics12071184.

13. Andreev DN, Khurmatullina AR, Maev IV, Bordin DS, Zaborovskiy AV, Abdulkhakov SR et al. Helicobacter pylori Antibiotic Resistance in Russia: A Systematic Review and Meta-Analysis. Antibiotics. 2025;14(5):524. https://doi.org/10.3390/antibiotics14050524.

14. Maev IV, Andreev DN. Molecular genetic predictors of resistance to antiHelicobacter pylori therapy. Ter Arkh. 2017;89(8):5–12. https://doi.org/10.17116/terarkh20178985-12.

15. Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577–585. https://doi.org/10.1080/14787210.2016.1178065.

16. Ishibashi F, Suzuki S, Nagai M, Mochida K, Morishita T. Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments. Gut Liver. 2023;17(5):684–697. https://doi.org/10.5009/gnl220429.

17. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30(30):134–140. https://doi.org/10.5829/idosi.wasj.2014.30.mett.61.

18. Maevsky IV, Samsonov AA, Andreev DN, Kochetov SA, Andreev NG, Dicheva DT. Modern aspects of the diagnosis and treatment of Helicobacter pylori infection (based on the Maastricht IV Consensus, Florence, 2010). Meditsinskiy Sovet. 2012;(8):10–19. (In Russ.) Available at: https://cyberleninka.ru/article/n/sovremennye-aspekty-diagnostiki-i-lecheniya-infektsii-helicobacter-pylori-po-materialam-konsensusamaastriht-iv-florentsiya-2010.

19. Maev IV, Kucheriavyĭ IuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: Review of world trends. Terapevticheskii Arkhiv. 2014;86(3):94–99. (In Russ.) Available at: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2014/3/030040-36602014316.

20. Andreev DN, Maev IV, Samsonov AA. The importance of probiotics in optimizing the efficacy and safety of Helicobacter pylori infection eradication therapy. Meditsinskiy Sovet. 2020(5):9–16. (In Russ.) https://doi.org/10.21518/2079-701X-2020-5-9-16.

21. Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L et al. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220–1229. https://doi.org/10.14309/ajg.0000000000001246.

22. Huguet JM, Ferrer-Barceló L, Suárez P, Barcelo-Cerda S, Sempere J, Saracino IM et al. Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management. United European Gastroenterol J. 2024;12(6):691–704. https://doi.org/10.1002/ueg2.12569.

23. Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy. Int J Mol Sci. 2020;21(3):1136. https://doi.org/10.3390/ijms21031136.

24. Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A metaanalysis. Exp Ther Med. 2015;9(3):707–716. https://doi.org/10.3892/etm.2015.2174.

25. Azam A, Qureshi MAM, Zahoor HS, Raza SM, Khan MM, Naeem U et al. A Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication. Microbiologyopen. 2025;14(6):e70166. https://doi.org/10.1002/mbo3.70166.

26. Auclair-Ouellet N, Tremblay A, Kassem O, Caballero-Calero SE, Bronner S, Binda S. Probiotics as Adjuvants to Standard Helicobacter pylori Treatment: Evidence for the Use of Lacidofil®, an Established Blend of Thoroughly Characterized Strains. Microorganisms. 2025;13(10):2223. https://doi.org/10.3390/microorganisms13102223.

27. Liu Y-H, Zhang J, Li D-H, Zhang Y-P, Li J, Guo Q-Q et al. The impact of probiotics on Helicobacter pylori eradication with bismuth quadruple therapy: A systematic review and meta-analysis. Int J Antimicrob Agents. 2025;66(6):107600. https://doi.org/10.1016/j.ijantimicag.2025.107600.

28. Yang Z, Zhou Y, Han Z, He K, Zhang Y, Wu D et al. The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses. Sci Rep. 2024;14(1):10069. https://doi.org/10.1038/s41598-024-59399-4.

29. Sitkin SI. Limosilactobacillus reuteri DSM 17648 as an adjuvant in the fight against Helicobacter pylori infection: Mechanisms of action, clinical efficacy, and prospects. Almanac of Clinical Medicine. 2026;54:1–16. (In Russ.) https://doi.org/10.18786/2072-0505-2026-54-001.

30. Ivashkin VT, Alekseyeva OP, Baranovsky AYu, Baranskaya YeK, Beloborodova YeV, Kolesov TA et al. The Role of Lactobacillus reuteri DSMZ17648 for Helicobacter pylori eradication therapy (Review of literature and advisory council resolution, February 28, 2018). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):33–38. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-3-33-38.

31. Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins. 2015;7(2):91–100. https://doi.org/10.1007/s12602-014-9181-3.

32. Mehling H, Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (PylopassTM) as a New Approach to Helicobacter pylori Control in Humans. Nutrients. 2013;5(8):3062–3073. https://doi.org/10.3390/nu5083062.

33. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105–110. https://doi.org/10.1111/j.1574-695X.2002.tb00541.x.

34. Mishra V, Dash D, Panda AK, Pathak SK. Evaluating probiotic monotherapy in Helicobacter pylori infection: A meta-analysis of randomized controlled trials with trial sequential analysis. Microb Pathog. 2026;213:108316. https://doi.org/10.1016/j.micpath.2026.108316.

35. Li M, Wang X, Dong X, Teng G, Dai Y, Wang W. Lactobacillus reuteri compared with placebo as an adjuvant in Helicobacter pylori eradication therapy: a meta-analysis of randomized controlled trials. Therap Adv Gastroenterol. 2024;17:17562848241258021. https://doi.org/10.1177/17562848241258021.

36. Uspensky YuP, Fomin YuA, Ivanov SV, Menaker IO. Evolution in the eradication therapy of HP-associated diseases. Going beyond the standards? RMJ. 2016;(17):1144–1152. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Evolyuciya_v_eradikacionnoy_terapii_NR-associirovannyh_zabolevaniy_Vyhod_za_ramki_standartov/.

37. Bakulina NV, Ilchishina TA, Bakulin IG, Anuchina YuG, Arkhipova SS, Gareginyan AA et al. Probiotics in Helicobacter pylori eradication regimens: current data and results of our own research. Consilium Medicum. 2019;21(8):58–64. (In Russ.) https://doi.org/10.26442/20751753.2019.8.190584.

38. Khlynov IB, Akimenko RI, Voronova EI, Garanina EV, Gurikova IA, Loseva ME et al. Possible role of Lactobacillus reuteri for eradication of Helicobacter pylori in adults in real clinical practice. Lechaschi Vrach. 2020;(2):19–22. (In Russ.) https://doi.org/10.26295/OS.2020.45.81.004.

39. Parth K, Prudhivi R, Palatheeya S, Abbas SK, Varsha K, Niharika BV et al. Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy. J Pharm Res Int. 2021;52(33):151–159. https://doi.org/10.9734/jpri/2021/v33i52b33611.

40. Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Heli­ cobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. https://doi.org/10.1111/hel.12856.

41. Ismail NI, Nawawi KNM, Hsin DCC, Hao KW, Mahmood NRKN, Chearn GLC et al. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2023;28(6):e13017. https://doi.org/10.1111/hel.13017.

42. Ivashkin V, Maev I, Poluektova E, Sinitsa A, Avalueva E, Mnatsakanyan M et al. Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri (Limosilactobacillus reuteri) DSM17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial. Clin Transl Gastro­ enterol. 2024;15(9):e1. https://doi.org/10.14309/ctg.0000000000000750.

43. Bordin DS, Voynovan IN, Homeriki SG, Yanova OB, Kim VA, Bystrovskaya EV et al. Efficiency and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori. Lechaschi Vrach. 2016;(5):106–110. (In Russ.) Available at: https://www.lvrach.ru/2016/05/15436483.

44. Musazadeh V, Nazari A, Faghfouri AH, Emami M, Kavyani Z, Zokaei M et al. The effectiveness of treatment with probiotics in Helicobacter pylori eradication: results from an umbrella meta-analysis on meta-analyses of randomized controlled trials. Food Funct. 2023;14(16):7654–7662. https://doi.org/10.1039/D3FO00300K.

45. Bordin DS, Voynovan IN, Kolbasnikov SV. Evidence base of Lactobacillus reuteri efficacy in the treatment of diseases associated with Helicobacter pylori. Experimental and Clinical Gastroenterology. 2016;(8):82–87. (In Russ.) Available at: https://www.nogr.org/jour/article/view/264.

46. Bordin DS, Kolbasnikov SV, Kononova AG, Voynovan IN. The role of probiotics in the treatment of diseases associated with Helicobacter pylori. Vrach. 2015;(3):23–27. (In Russ.) Available at: https://vrachjournal.ru/ru/25877305-2015-03-06.

47. Liang B, Yuan Y, Peng X-J, Liu X-L, Hu X-K, Xing D-M. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol. 2022;12:1042070. https://doi.org/10.3389/fcimb.2022.1042070.

48. Maev IV, Andreev DN, Fomenko AK, Podporin MS, Lyamina SV, Zaborovsky AV et al. Trends of antibiotic resistance of Helicobacter pylori in Moscow. Ter Arkh. 2025;97(2):163–168. https://doi.org/10.26442/00403660.2025.02.203193.

49. Andreev DN, Khurmatullina AR, Maev IV, Bordin DS, Zaborovsky AV, Kucheryavyy YA et al. Tailored Therapy vs. Empirical Therapy for Helicobacter pylori Eradication: An Umbrella Review of Systematic Reviews and MetaAnalyses. J Pers Med. 2025;15(10):458. https://doi.org/10.3390/jpm15100458.

50. Casas Deza D, Alcedo J, Lafuente M, López FJ, Perez-Aisa Á, Pavoni M et al. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). Am J Gastroenterol. 2025;120(11):2644–2659. https://doi.org/10.14309/ajg.0000000000003351.

51. Nyssen OP, Jonaitis L, Pérez-Aísa Á, Tepes B, Mahmudov U, Voynovan I et al. Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp-EuReg). Helicobacter. 2026;31(2):e70119. https://doi.org/10.1111/hel.70119.

52. Zhang Y, Tu M, Long P, Zheng J, Du G, Xiao S et al. Efficacy of probiotics pretreatment in Helicobacter pylori eradication therapy: a systematic review and meta-analysis of clinical outcomes. Ann Med. 2025;57(1):2533431. https://doi.org/10.1080/07853890.2025.2533431.